This page shows the latest WE UK news and features for those working in and with pharma, biotech and healthcare.
Dr Kamran Iqbal, head of medical affairs, global rare diseases, Chiesi UK and Ireland, said: “We are pleased that eligible patients in England and Wales will now be able to access ... The discovery and availability of new treatment options is crucial
The UK poll revealed that only 60% of adults know that dementia is a cause of death. ... Alzheimer’s Research UK has published the results of a nationwide survey of public perceptions of dementia in its Dementia Attitudes Monitor.
younger. Over ten years, 500 patients with cervical cancer participated in the trial across hospitals in the UK, Mexico, India, Italy and Brazil. ... Dr Iain Foulkes, executive director, research and innovation, at Cancer Research UK, said: “We’re
Several companies and organisations have supported the development of mRNA. The BioIndustry Association (BIA) has revealed how the UK is set to become a global leader in mRNA medicine in a ... By raising awareness of the potential of the UK ecosystem in
AD is a progressive and irreversible neurodegenerative disorder that currently affects around 900, 000 people in the UK. ... Emma Stone, research programmes manager at Alzheimer’s Research UK, commented: “It is essential we keep investing into
PsA and axSpA are two forms of chronic inflammatory arthritis, affecting over 800, 000 people in the UK combined. ... Claire Brading, managing director UK and Ireland at UCB, said: “We are proud that [Bimzelx], discovered right here in the UK, has been
More from news
Approximately 0 fully matching, plus 318 partially matching documents found.
One payer based in the UK remarked: “[The UK subscription model] hopefully means we can restrict use without detriment to development.” Another said: “I personally think that restricting use whilst encouraging ... The white paper includes data
In extreme cases we are seeing charities provide bursaries to hospitals to ensure patients receive new therapies. ... How do we do this? The simple answer is to demonstrate our commitment to value-based healthcare.
Point of care CRP tests are one of the most effective tools we have against unnecessary antibiotic prescribing in primary care. ... Point of care CRP testing has demonstrated its efficacy in a number of pilot projects in the UK.
We are fortunate that, in the UK, the government and the NHS committed early to embedding a personalised medicine approach across the health system. ... More than this, we have been crucial to their development. I’ve undertaken hundreds of clinical
We do this through a range of initiatives, including the Dementia Consortium and the Alzheimer’s Research UK Drug Discovery Alliance. ... This will determine whether this drug is licensed in the US, but for the UK we will have to wait longer and see
More from intelligence
Approximately 0 fully matching, plus 56 partially matching documents found.
Sandoz, the generics division of Novartis, has announced the appointment of Diane DiGangi Trench as its new UK country head. ... I am delighted to join the UK organisation as Country Head as we celebrate our 15 years in biosimilar medicines,” commented
Keith-Roach joins the AZ UK team following a number of in-country, above-country and global therapy area leadership positions. ... I’m very pleased to join our team in the UK. We have a deep-rooted presence here at the heart of the UK life sciences
Prior to his time with Pfizer, Maine was head of government affairs at Wyeth Pharmaceuticals - later acquired by Pfizer - and has held other roles withmanaging director for Edelman UK, said: “We ... are very excited about Alan joining Edelman as he
Public relations group WE UK has appointed Catherine Devaney to head up its health sector business to bolster the agency’s global health offering. ... Marcus Sorour, general manager at WE UK, said: “The momentum we are experiencing in our health
Andrea Sobrio, managing partner, Executive Insight, said: “With his extensive background, David is well positioned to play an integral role in growing the group’s practice for UK-based international clients. ... We are honoured to welcome David to
More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.
33. Within the UK at least, we are increasingly seeing more and more women in the public eye open up about their experiences with women’s health: including television presenter Naga ... 40. Will we see femtech branch out even further to fill this gap?
We work closely with our clients, becoming an extension of their teams, to ensure the value of their products is appropriately communicated. ... Please email info@mtechaccess.co.uk to discuss how we can support you with your JCA dossier.
nspm is a successful and dynamic medical communications company with offices in Switzerland and the UK. ... We provide a complete range of medical writing, project management and strategic medical communications solutions for the pharmaceutical and
As the Flexible Working Bill gets written into UK law, we took a look at what this means for businesses of all sizes and specialities. ... We’ve seen this with our own team and we’re excited to see how this new bill will help reshape the working
The filmmakers followed two leukaemia patients in first-in-human trials in the UK. ... To complement our review, we reached out to 12 payers in our network with advanced therapy expertise from across the UK, France, Germany, Spain, and Italy.
More from PMHub
Approximately 0 fully matching, plus 96 partially matching documents found.
No results were found
We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...